2021-11-16-世界卫生组织-Cervical_cancer_Yemen_2021_country_profile_1页_63kb

Yemen Cervical Cancer Profile Summary

Morbidity and Mortality

• Crude cervical cancer incidence: 1.5 per 100,000 women (2020).
• Age-standardized incidence: 2.5 per 100,000 women (2020).
• Cumulative risk: 0.3% among ages 0–74 (2020).
• Deaths: Approximately 75,900 cases in 2019.
• Mortality-to-incidence ratio: 0.68 (2020).
• A population-based cancer registry does not exist (2021).

Primary Prevention

• HPV vaccination coverage: 8% fully vaccinated among target girls, 8% for first dose out of final dose.
• HPV not included in national vaccination schedule.
• Vaccination programme was introduced with year and primary target unspecified.
• Risk factors: Data on tobacco use prevalence, condom use, HIV incidence available but partial.

Secondary Prevention (Screening)

• No national cervical cancer screening programme exists (2021).
• <10% of women aged 30–49 years reported being screened in the last 5 years.
• Guidelines exist to strengthen early symptom detection at primary health care (2021), but referral systems to secondary and tertiary care are not defined (2021).

Treatment and Supportive Care

• National guidelines on cervical cancer management exist (2021).
• Limited resources: 5 radiotherapy units, 5 brachytherapy units per 10,000 cancer patients.
• Medical staff: >70% availability per 10,000 cancer patients.
• Cancer centers, including specialized roles (e.g., surgeons, radiation oncologists, radiologists, pathology services), are present but constrained.
• Limited palliative care access.

WHO Elimination Strategy Targets

• Yemen is part of the WHO global strategy; details for targets include improving immunization coverage, screening rates, and death reduction by 2030.

Data Resolution

• Some data (e.g., HPV introduction year, vaccination rates details) not fully specified; use age, risk factor, and service indicators cautiously due to missing information.